Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders.

Novel technology in the nanomedicine field is expected to develop innovative products as targeted drug-delivery approaches. Targeted drug delivery of various drugs for the treatment of cancer, AIDS and brain disorders is the primary research area in which nanomedicines have a major role and need. This review is concerned with emerging targeted nanomedicines (polymeric nanoparticles, solid lipid nanoparticles, polymeric micelles, dendrimers, liposomes, gold nanoparticles and magnetic nanoparticles) and multifunctional carriers capable of combining targeted drug delivery and imaging (polymeric micelles, dendrimers and magnetic nanoparticles) in the field of pharmaceutical applications. The significant toxicity issues associated with these nanomedicines are also explored here.

[1]  Alexander V Kabanov,et al.  Optimal Structure Requirements for Pluronic Block Copolymers in Modifying P-glycoprotein Drug Efflux Transporter Activity in Bovine Brain Microvessel Endothelial Cells , 2003, Journal of Pharmacology and Experimental Therapeutics.

[2]  M. Bergeron,et al.  Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1. , 2000, Biochimica et biophysica acta.

[3]  C Alexiou,et al.  Clinical applications of magnetic drug targeting. , 2001, The Journal of surgical research.

[4]  M. Simionescu,et al.  Designing of ‘intelligent’ liposomes for efficient delivery of drugs , 2002, Journal of cellular and molecular medicine.

[5]  Vladimir P. Torchilin,et al.  Immunomicelles: Targeted pharmaceutical carriers for poorly soluble drugs , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  V. Torchilin,et al.  Biodegradable long-circulating polymeric nanospheres. , 1994, Science.

[7]  Marie-Hélène Dufresne,et al.  Block copolymer micelles: preparation, characterization and application in drug delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[8]  J M Wilkinson,et al.  Nanotechnology applications in medicine. , 2003, Medical device technology.

[9]  Giuseppe Altavilla,et al.  DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination. , 2006, Vaccine.

[10]  T. Mccarthy,et al.  Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. , 2005, Molecular pharmaceutics.

[11]  M. Bednarski,et al.  Tumor Regression by Targeted Gene Delivery to the Neovasculature , 2002, Science.

[12]  Y. Cai,et al.  Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[13]  N. Nishiyama,et al.  Differential gene expression profile between PC-14 cells treated with free cisplatin and cisplatin-incorporated polymeric micelles. , 2003, Bioconjugate chemistry.

[14]  D. Markovitz,et al.  The role of mononuclear phagocytes in HTLV-III/LAV infection. , 1986, Science.

[15]  L. Tiefenauer,et al.  Antibody-magnetite nanoparticles: in vitro characterization of a potential tumor-specific contrast agent for magnetic resonance imaging. , 1993, Bioconjugate chemistry.

[16]  F M Muggia,et al.  Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  R. J. Lee,et al.  Targeted drug delivery via the folate receptor. , 2000, Advanced drug delivery reviews.

[18]  V. Torchilin Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[19]  Yechezkel Barenholz,et al.  Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.

[20]  Jean-Marie Devoisselle,et al.  Magnetic nanoparticles and their applications in medicine. , 2006, Nanomedicine.

[21]  R. Jain Delivery of molecular and cellular medicine to solid tumors. , 2001, Advanced drug delivery reviews.

[22]  J. Kreuter,et al.  Nanoparticulate systems for brain delivery of drugs. , 2001 .

[23]  V. Torchilin Targeted pharmaceutical nanocarriers for cancer therapy and imaging , 2007, The AAPS Journal.

[24]  M. S. Muthu,et al.  Preparation and characterization of nanoparticles containing an atypical antipsychotic agent. , 2007, Nanomedicine.

[25]  H. Fessi,et al.  Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. , 2005, Critical reviews in therapeutic drug carrier systems.

[26]  Jinming Gao,et al.  Folate-encoded and Fe3O4-loaded polymeric micelles for dual targeting of cancer cells , 2008 .

[27]  Robert J. Levy,et al.  Nanoparticle drug delivery system for restenosis , 1997 .

[28]  Thommey P. Thomas,et al.  PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. , 2006, Biomacromolecules.

[29]  Hari Singh Nalwa,et al.  Nanotechnology and health safety--toxicity and risk assessments of nanostructured materials on human health. , 2007, Journal of nanoscience and nanotechnology.

[30]  M. Swartz,et al.  The physiology of the lymphatic system. , 2001, Advanced drug delivery reviews.

[31]  P. Couvreur,et al.  Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles , 1992, Investigational New Drugs.

[32]  R. Gurny,et al.  Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles. , 2007, International journal of pharmaceutics.

[33]  S. B. Tiwari,et al.  A review of nanocarrier-based CNS delivery systems. , 2006, Current drug delivery.

[34]  Robert Gurny,et al.  Drug-loaded nanoparticles : preparation methods and drug targeting issues , 1993 .

[35]  J. Xue,et al.  Targeted and intracellular delivery of paclitaxel using multi-functional polymeric micelles. , 2007, Biomaterials.

[36]  Hongzhe Sun,et al.  Transferrin-mediated gold nanoparticle cellular uptake. , 2005, Bioconjugate chemistry.

[37]  J. Kreuter Nanoparticles--a historical perspective. , 2007, International journal of pharmaceutics.

[38]  N. K. Jain,et al.  Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[39]  S. Zalipsky Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. , 1995, Bioconjugate chemistry.

[40]  V. Venkateswarlu,et al.  Novel delivery systems for drug targeting to the brain , 2004 .

[41]  H. Benson,et al.  Drug delivery across the blood-brain barrier. , 2004, Current drug delivery.

[42]  V. Torchilin,et al.  Micellar Nanocarriers: Pharmaceutical Perspectives , 2006, Pharmaceutical Research.

[43]  D. Begley Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. , 2004, Pharmacology & therapeutics.

[44]  Hua Ai,et al.  Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. , 2006, Nano letters.

[45]  Miklós Tóth,et al.  Animal Models of Complement-Mediated Hypersensitivity Reactions to Liposomes and Other Lipid-Based Nanoparticles , 2007, Journal of liposome research.

[46]  Daniel G. Anderson,et al.  Biodegradable polymeric vectors for gene delivery to human endothelial cells. , 2006, Bioconjugate chemistry.

[47]  A. C. Hunter,et al.  Nanomedicine: current status and future prospects , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  C. Murphy,et al.  Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. , 2005, Small.

[49]  K. Mäder,et al.  Solid lipid nanoparticles: production, characterization and applications. , 2001, Advanced drug delivery reviews.

[50]  M. Roco Nanotechnology: convergence with modern biology and medicine. , 2003, Current opinion in biotechnology.

[51]  Robert Langer,et al.  Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. , 2007, Nanomedicine.

[52]  M. S. Muthu,et al.  Studies on biodegradable polymeric nanoparticles of risperidone: in vitro and in vivo evaluation. , 2008, Nanomedicine.

[53]  M. Ricci,et al.  Solid lipid nanoparticles for targeted brain drug delivery. , 2007, Advanced drug delivery reviews.

[54]  D. Lasič Novel applications of liposomes. , 1998, Trends in biotechnology.

[55]  D. Maysinger,et al.  Micellar Nanocontainers Distribute to Defined Cytoplasmic Organelles , 2003, Science.

[56]  C. Schengrund,et al.  Dendrimers and antivirals: a review. , 2005, Current drug targets. Infectious disorders.

[57]  S. Moghimi,et al.  Cellular Distribution of Nonionic Micelles , 2004, Science.

[58]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[59]  Anna Moore,et al.  In vivo imaging of siRNA delivery and silencing in tumors , 2007, Nature Medicine.

[60]  Thommey P. Thomas,et al.  HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. , 2006, Bioconjugate chemistry.

[61]  F. Calon,et al.  Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. , 2003, Human gene therapy.

[62]  K. Neoh,et al.  Synthesis and in vitro anti-cancer evaluation of tamoxifen-loaded magnetite/PLLA composite nanoparticles. , 2006, Biomaterials.

[63]  Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting , 2008 .

[64]  P. Couvreur,et al.  Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.

[65]  T. Xu,et al.  Design, synthesis and potent pharmaceutical applications of glycodendrimers: a mini review. , 2007, Current drug discovery technologies.

[66]  K. Strebhardt,et al.  Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. , 2006, Biomaterials.

[67]  T. Stinchcombe,et al.  Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. , 2007, Nanomedicine.

[68]  R. Cavalli,et al.  Intravenous Administration to Rabbits of Non-stealth and Stealth Doxorubicin-loaded Solid Lipid Nanoparticles at Increasing Concentrations of Stealth Agent: Pharmacokinetics and Distribution of Doxorubicin in Brain and Other Tissues , 2002, Journal of drug targeting.

[69]  John W. Park,et al.  Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. , 1997, Biochemistry.

[70]  Y. Kuo,et al.  Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. , 2007, International journal of pharmaceutics.

[71]  M. Bally,et al.  Preparation, characterization, and biological analysis of liposomal formulations of vincristine. , 2005, Methods in enzymology.

[72]  M. Sastry,et al.  Gold nanoparticles as carriers for efficient transmucosal insulin delivery. , 2006, Langmuir : the ACS journal of surfaces and colloids.

[73]  Erkki Ruoslahti,et al.  Organ targeting In vivo using phage display peptide libraries , 1996, Nature.

[74]  Lisa Brannon-Peppas,et al.  Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery , 1995 .

[75]  Seungpyo Hong,et al.  The Binding Avidity of a Nanoparticle-based Multivalent Targeted Drug Delivery Platform , 2022 .

[76]  J. Feijen,et al.  The effect of phagocytosis of poly(L-lactic acid) fragments on cellular morphology and viability. , 1993, Journal of biomedical materials research.

[77]  Russell J Mumper,et al.  Brain uptake of thiamine-coated nanoparticles. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[78]  W. Mark Saltzman,et al.  Nanosystems for simultaneous imaging and drug delivery to T cells , 2007, The AAPS Journal.

[79]  Rubiana M Mainardes,et al.  PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. , 2005, International journal of pharmaceutics.

[80]  V. Rotello,et al.  Stability of Gold Nanoparticle‐Bound DNA toward Biological, Physical, and Chemical Agents , 2006, Chemical biology & drug design.

[81]  M. Grinstaff,et al.  Therapeutic and diagnostic applications of dendrimers for cancer treatment. , 2008, Advanced drug delivery reviews.

[82]  M. Bergeron,et al.  Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. , 2002, Biochimica et biophysica acta.

[83]  M. Baccarani,et al.  Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia , 2002, Leukemia.

[84]  Afsaneh Lavasanifar,et al.  Amphiphilic block copolymers for drug delivery. , 2003, Journal of pharmaceutical sciences.

[85]  R. Costo,et al.  The preparation of magnetic nanoparticles for applications in biomedicine , 2003 .

[86]  V. Venkateswarlu,et al.  Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[87]  M. Samanta,et al.  Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease , 2008, Brain Research.

[88]  Theresa M Allen,et al.  Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. , 2002, Cancer research.

[89]  Erkki Ruoslahti,et al.  αv Integrins as receptors for tumor targeting by circulating ligands , 1997, Nature Biotechnology.

[90]  Xiao-bing Xiong,et al.  Polymeric micelles for drug targeting , 2007, Journal of drug targeting.